Klotho Peptides: Research & Studies
Scientific evidence, clinical trials, and research findings
๐TL;DR
- โข4 clinical studies cited
- โขOverall evidence level: low
- โข7 research gaps identified
Research Studies
A Klotho-derived peptide protects against kidney fibrosis by targeting TGF-beta signaling
Yuan Q, Tang B, Zhang C (2022) โข Nature Communications
Identified KP1, a 30-amino-acid klotho-derived peptide, through systematic screening of KL1 domain peptides. KP1 blocked TGF-beta/TbetaR2 engagement, repressed fibroblast activation, and ameliorated kidney fibrosis in mouse UUO models. IV-administered KP1 showed preferential accumulation in injured kidneys.
Key Findings
- KP1 identified from screen of 18 overlapping KL1 domain peptides as anti-fibrotic lead
- KP1 binds TGF-beta receptor type 2 and blocks TGF-beta/TbetaR2 engagement
- Blocked Smad2/3 phosphorylation and MAPK activation downstream of TGF-beta
- IV-injected KP1 preferentially accumulated in injured kidneys and preserved renal function
- Restored endogenous klotho expression in fibrotic kidneys
Limitations: Mouse UUO model only; no pharmacokinetic characterization; dose-response relationship not fully established; no human data; single research group
Klotho-derived peptide 6 ameliorates diabetic kidney disease by targeting Wnt/beta-catenin signaling
Zhou L, Mo H, Miao J, et al. (2022) โข Kidney International
Demonstrated that KP6, a klotho-derived peptide, ameliorates diabetic kidney disease by binding Wnt ligands and disrupting Wnt/LRP6 engagement. Chronic KP6 infusion reversed proteinuria and kidney damage in both type 1 and type 2 diabetic mouse models. Scrambled-sequence control was inactive.
Key Findings
- KP6 bound Wnt ligands and disrupted Wnt/LRP6 engagement to inhibit beta-catenin signaling
- Reversed established proteinuria in STZ-induced type 1 and db/db type 2 diabetic mice
- Attenuated glomerular hypertrophy, podocyte damage, and fibrotic lesions
- Scrambled-sequence KP6 failed to bind Wnts and did not ameliorate DKD
- Did not affect serum phosphorus and calcium levels
Limitations: Mouse models only; chronic infusion route not clinically practical; no pharmacokinetic data; no human data; mechanistic specificity to kidney vs other Wnt-dependent tissues not characterized
Longevity factor klotho enhances cognition in aged nonhuman primates
Castner SA, Gupta S, Wang D, et al. (2023) โข Nature Aging
Landmark study demonstrating that a single systemic injection of low-dose klotho protein (KL1 domain, not KP1/KP6 peptides) enhanced memory in aged rhesus macaques. Effects were observed within 4 hours and persisted for approximately 2 weeks. High doses were not effective.
Key Findings
- Single low-dose klotho injection enhanced memory in aged nonhuman primates
- High-dose klotho did not enhance cognition (inverted U dose-response)
- Cognitive enhancement observed within 4 hours of injection
- Effects persisted for approximately 2 weeks after single dose
Limitations: Used full KL1 domain protein (~450 aa), not short klotho peptides; small number of animals; specific dose not publicly disclosed; mechanism of peripheral-to-central signal transduction not fully elucidated
Life extension factor klotho enhances cognition
Dubal DB, Yokoyama JS, Zhu L, et al. (2014) โข Cell Reports
Foundational study showing that the human KLOTHO gene variant KL-VS is associated with enhanced cognition in heterozygous carriers. Transgenic mice overexpressing klotho performed better in learning and memory tests, with enhanced long-term potentiation and enriched synaptic GluN2B.
Key Findings
- KL-VS heterozygosity associated with enhanced cognition in humans independent of age
- Transgenic klotho-overexpressing mice showed improved learning and memory
- Klotho enhanced long-term potentiation and enriched synaptic GluN2B (NMDA receptor subunit)
- GluN2B blockade abolished klotho-mediated cognitive effects
Limitations: Human data correlational (KL-VS genotype); mouse overexpression model; mechanism of peripheral klotho affecting CNS function not fully defined; no intervention trial in humans
Unlock full research citations
Free access to all clinical studies, citations, and evidence summaries.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
Community Experience Data
See how community outcomes align with (or diverge from) the research findings above.
Based on 10+ community reports
View community protocolsExplore research gaps across all peptides โ | View clinical trial pipeline โ
๐Research Gaps & Future Directions
- โขNo human clinical trials for any klotho peptide or klotho protein therapy
- โขPharmacokinetic parameters (half-life, distribution, clearance) not characterized for KP1 or KP6
- โขLong-term safety profile of klotho peptides completely unknown
- โขWhether small klotho peptides (KP1, KP6) have cognitive effects similar to full-length KL1 domain not tested
- โขOptimal dosing, route of administration, and frequency for clinical translation not determined
- โขOff-target effects of TGF-beta or Wnt pathway inhibition in non-kidney tissues not systematically assessed
- โขManufacturing scalability for GMP-grade klotho peptide production not established
Research Overview#
Klotho peptide research encompasses two distinct but related areas: (1) small synthetic peptides (KP1, KP6) derived from the klotho protein for kidney disease applications, and (2) the full klotho protein or its KL1 domain for cognitive enhancement. All research remains preclinical. The evidence level is classified as low due to the exclusively preclinical nature of the data, despite publication in high-impact journals (Nature Communications, Kidney International, Nature Aging, Cell Reports).
Kidney Disease Research#
KP1 for Kidney Fibrosis (Nature Communications 2022)#
Yuan et al. (PMID 35064106) reported the systematic identification and characterization of KP1:
Peptide discovery approach: The KL1 domain of human alpha-klotho was divided into 18 overlapping peptides of approximately 30 amino acids each. These were screened for anti-fibrotic activity in TGF-beta-stimulated fibroblasts. KP1 (residues 57-86) emerged as the most potent inhibitor of fibroblast activation.
Mechanism: KP1 binds directly to TGF-beta receptor type 2 (TbetaR2), physically blocking TGF-beta ligand engagement. This prevents downstream Smad2/3 phosphorylation and MAPK activation, effectively shutting down the TGF-beta signaling cascade that drives organ fibrosis.
In vivo efficacy: In the unilateral ureteral obstruction (UUO) model of kidney fibrosis in mice, IV-administered KP1:
- Preserved kidney function
- Repressed TGF-beta signaling markers
- Ameliorated renal fibrosis
- Showed preferential accumulation in injured kidneys
- Restored endogenous klotho expression, which is typically suppressed in fibrotic kidneys
Follow-up study (PMID 38164143): KP1 was subsequently shown to inhibit cellular senescence in the fibrotic kidney by restoring klotho expression via posttranscriptional regulation mediated by miR-223-3p and lncRNA-TUG1.
KP6 for Diabetic Kidney Disease (Kidney International 2022)#
Zhou et al. (PMID 35644285) characterized KP6 for diabetic kidney disease:
Target pathway: Unlike KP1 (which targets TGF-beta), KP6 targets the Wnt/beta-catenin signaling pathway, which is aberrantly activated in diabetic kidney disease.
Mechanism: KP6 binds directly to Wnt ligands, preventing their engagement with the LRP6 co-receptor. This disrupts canonical Wnt/beta-catenin signaling, reducing beta-catenin nuclear translocation and transcriptional activity.
In vivo results: Chronic KP6 infusion in diabetic mice:
- Reversed established proteinuria in both STZ-induced (type 1) and db/db (type 2) diabetes models
- Attenuated glomerular hypertrophy and mitigated podocyte damage
- Ameliorated glomerulosclerosis and interstitial fibrotic lesions
- Did not affect serum phosphorus or calcium levels (suggesting kidney-specific action)
Controls: Critically, a scrambled-sequence KP6 peptide failed to bind Wnt ligands and showed no therapeutic effect, confirming that KP6's activity is sequence-specific.
Cognitive Enhancement Research#
Dubal et al. (Cell Reports 2014)#
The foundational study (PMID 24813892) established the connection between klotho and cognition:
- The KL-VS variant of the human KLOTHO gene is associated with enhanced cognition in heterozygous carriers
- Transgenic mice overexpressing klotho showed improved performance in multiple learning and memory tests
- Klotho enhanced long-term potentiation (LTP) in the hippocampus
- The mechanism involves enrichment of synaptic GluN2B, an NMDA receptor subunit critical for learning and memory
- GluN2B blockade abolished klotho-mediated cognitive enhancement
Castner et al. (Nature Aging 2023)#
The landmark primate study (PMID 37400721) translated the mouse findings to aged nonhuman primates:
- A single systemic injection of low-dose klotho protein (KL1 domain) enhanced memory in aged rhesus macaques
- High-dose klotho did not enhance cognition, suggesting an inverted U dose-response
- Cognitive enhancement was detectable within 4 hours of injection
- Effects persisted for approximately 2 weeks from a single dose
- This used the full KL1 domain (~450 amino acids), not the small KP1/KP6 peptides (~30 amino acids)
Evidence Quality Assessment#
| Evidence Criterion | Assessment | Details |
|---|---|---|
| Study design | Preclinical only | Mouse models and nonhuman primates |
| Publication quality | High | Nature Communications, Kidney International, Nature Aging, Cell Reports |
| Mechanism | Well-characterized | TGF-beta (KP1), Wnt (KP6), GluN2B (KL1 protein) clearly defined |
| In vivo efficacy | Demonstrated | Multiple mouse models; primate data for full protein |
| Controls | Appropriate | Scrambled-sequence peptide controls used |
| Clinical translation | Not initiated | No IND filings or clinical trial registrations |
| Safety data | Minimal | Limited to absence of gross toxicity in animal studies |
| Independent replication | Limited | KP1 cellular senescence follow-up from same group |
Related Reading#
Frequently Asked Questions About Klotho Peptides
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.